Sunnyvale, CA – January 3, 2013 – Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals, today announced that melphalan intraocular injection, the company’s investigational product for the treatment…
Sunnyvale, CA (April 13, 2017) – Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced the submission of a New Drug Application (NDA) to the United…
SUNNYVALE, Calif–Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that Dr. Vernon Wong, the Company’s founder, Chairman and inventor of the Verisome® technology has been honored…
Detailed Results to be Presented at 2015 ASCRS-ASOA Symposium & Congress Sunnyvale, CA (April 6, 2015) – Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug delivery platform to develop unique intraocular eye-care therapeutics, today announced…
Icon Bioscience Reports Last Patient Out in its Phase 3 Study Of IBI-10090 as a Dropless, Sustained-released Therapeutic for Inflammation Associated With Cataract Surgery IBI-10090 Is The First Drug Candidate Utilizing the Verisome®Delivery Technology Sunnyvale, CA (OCTOBER 6, 2014) –…
Sunnyvale, CA (April 20, 2015) – Icon Bioscience Inc., a specialty biopharmaceutical company focused on utilizing its patented and proprietary Verisome® extended-release drug delivery platform to develop unique intraocular eye-care therapeutics, today reported data from its pivotal Phase 3 clinical…
PDUFA date set for February 12, 2018 Newark, CA (June 26, 2017) – Icon Bioscience Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that it has received…
Sunnyvale, CA (June 30, 2014) – Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced the completion of patient enrollment in its pivotal phase 3 study of…
SUNNYVALE, Calif.–Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug delivery platform to develop unique intraocular eye-care therapeutics, today announced that David S. Tierney, MD joined the Company as President & Chief Executive Officer. “I expect…
SUNNYVALE, Calif.– Icon Bioscience, Inc., a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today reported that IBI-10090, the Company’s lead pipeline product, is in a pivotal Phase 3 study as a…
My Canadian Pharmacy is an informative service. All the information should not be used in the purposes to establish a diagnosis and prescribe a treatment plan. Our company is a vendor, not a drug manufacturer. We cooperate with drug manufacturers who distribute their products to us. We have no relation with Icon Bioscience and Verisome. They move to another domain. We bear no responsibility for any damage brought to your health. All the questions related to the drug quality should be addressed to the drug manufacturer directly.